CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
Skip the Contents menu


Skip the Resources menu


U.S. Department of Health and Human Services

Fact Sheets

Return to Fact Sheets Main Menu
(PDF - 134k)

Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons
Last Updated: March 2003


In February 2003, the American Thoracic Society (ATS), the Centers for Diseases Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) released new guidelines for the treatment of TB. This fact sheet will provide key points from these guidelines; however, please refer to the Treatment of Tuberculosis1 for complete recommendations.

The management of HIV-related tuberculosis (TB) disease is complex. Although the treatment of TB in persons with HIV is essentially the same as for patients without HIV, there are some important differences.

Recommended Regimen

The recommended treatment of TB disease in HIV-infected adults (when the disease is caused by organisms that are known or presumed to be susceptible to first-line drugs) is a 6-month regimen consisting of

  • An initial phase of isoniazid (INH), a rifamycin (see Drug Interactions below), pyrazinamide (PZA), and ethambutol (EMB) for the first 2 months.
  • A continuation phase of INH and a rifamycin for the last 4 months.

Patients with advanced HIV (CD4 counts < 100/µl) should be treated with daily or three-times-weekly therapy in both the initial and the continuation phases. Twice weekly therapy may be considered in patients with less-advanced immunosuppression (CD4 counts ≥ 100/µl). Once-weekly INH/rifapentine in the continuation phase should not be used in any HIV-infected patient.

Six months should be considered the minimum duration of treatment for adults with HIV, even for patients with culture-negative TB. Prolonging treatment to 9 months (extend continuation phase to 7 months) for HIV-infected patients with delayed response to therapy (e.g., culture positive after 2 months of treatment) should be strongly considered.

Drug Interactions

A major concern in treating TB in HIV-infected persons is the interaction of rifampin (RIF) with certain antiretroviral agents (some protease inhibitors [PIs] and nonnucleoside reverse transcriptase inhibitors [NRTIs]). Rifabutin, which has fewer problematic drug interactions, may be used as an alternative to RIF.

As new antiretroviral agents and more pharmacokinetic data become available, these recommendations are likely to be modified.

Case Management

Directly observed therapy (DOT) and other adherence promoting strategies should be used in all patients with HIV-related TB. Whenever possible, the care for HIV-related TB should be provided by or in consultation with experts in management of both TB and HIV. The care for persons with HIV-related TB should include close attention to the possibility of TB treatment failure, antiretroviral treatment failure, paradoxical reactions of TB (e.g., temporary worsening of signs or symptoms of TB), side effects for all drugs used, and drug toxicities associated with increased serum concentrations of rifamycins.

For More Information

1. Centers for Disease Control and Prevention. Treatment of Tuberculosis. MMWR 2003;52(No. RR-11).


2. Guidance documents for the medical management of HIV

3. Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. MMWR 2004: 53 (No. 2)

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis


Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention


Back to Top of Page

If you would like to order any of the DTBE publications please visit the online order form.

You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348

Skip Bottom Nav Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA |
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: